2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Cardiotoxicity
7
Lymphoma, Non-Hodgkin
5
Breast Neoplasms
5
Neoplasms
4
Lymphoma
4
Prostatic Neoplasms
3
Myelodysplastic Syndromes
3
Lung Neoplasms
3
Leukemia
3
Hematologic Neoplasms
3
Heart Failure
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Rectal Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Lymphoma, B-Cell
2
Leukemia, Myeloid, Acute
2
Dyslipidemias
2
Colonic Neoplasms
2
Cardiovascular Diseases
2
Carcinoma in Situ
2
Burkitt Lymphoma
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Ventricular Dysfunction, Left
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Interventions
Cyclophosphamide
87
fludarabine phosphate
86
Peripheral Blood Stem Cell Transplantation
71
Mycophenolic Acid
58
Tacrolimus
57
Busulfan
57
Whole-Body Irradiation
55
Antilymphocyte Serum
47
Cyclosporine
46
fludarabine
39
Methotrexate
38
Filgrastim
38
Melphalan
32
ruxolitinib
30
Cytarabine
30
Radiotherapy
27
Azacitidine
23
Etoposide
21
Methylprednisolone
20
Cord Blood Stem Cell Transplantation
18
Specimen Handling
15
Sirolimus
15
Granulocyte Colony-Stimulating Factor
15
Decitabine
15
Biopsy
15
Flow Cytometry
14
Cyclosporins
14
Alemtuzumab
14
thymoglobulin
13
venetoclax
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
Electrocardiography
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled